DE602006007967D1 - Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon - Google Patents

Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon

Info

Publication number
DE602006007967D1
DE602006007967D1 DE602006007967T DE602006007967T DE602006007967D1 DE 602006007967 D1 DE602006007967 D1 DE 602006007967D1 DE 602006007967 T DE602006007967 T DE 602006007967T DE 602006007967 T DE602006007967 T DE 602006007967T DE 602006007967 D1 DE602006007967 D1 DE 602006007967D1
Authority
DE
Germany
Prior art keywords
epitop
muted
joint
applications
chain antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006007967T
Other languages
English (en)
Inventor
Beka Solomon
Sara Orgad
Itai Benhar
Ronit Rosenfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of DE602006007967D1 publication Critical patent/DE602006007967D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602006007967T 2005-03-25 2006-03-23 Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon Active DE602006007967D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66496705P 2005-03-25 2005-03-25
US69891905P 2005-07-14 2005-07-14
PCT/IL2006/000372 WO2006100681A2 (en) 2005-03-25 2006-03-23 Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses

Publications (1)

Publication Number Publication Date
DE602006007967D1 true DE602006007967D1 (de) 2009-09-03

Family

ID=36617330

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006007967T Active DE602006007967D1 (de) 2005-03-25 2006-03-23 Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon

Country Status (6)

Country Link
US (2) US8039594B2 (de)
EP (1) EP1863846B1 (de)
JP (1) JP2008533986A (de)
AT (1) ATE437185T1 (de)
DE (1) DE602006007967D1 (de)
WO (1) WO2006100681A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039594B2 (en) 2005-03-25 2011-10-18 Ramot At Tel-Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses
EP2054515B1 (de) * 2006-07-21 2012-01-11 Ramot at Tel-Aviv University Ltd. Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten
WO2008093331A1 (en) * 2007-01-29 2008-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antibody conjugates for circumventing multi-drug resistance
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
EP2573565A1 (de) 2011-09-23 2013-03-27 Gerhard Matthias Kresbach Immunnachweisverfahren für gemeinsame Epitope von zwei oder mehr Analyten in Proben mit komplexen Zusammensetzungen, Vorrichtung und Kit zum Ermöglichen dieses Immunnachweisverfahrens
CA2980292A1 (en) * 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
US10976306B2 (en) 2015-06-19 2021-04-13 Tokyo University Of Science Foundation Protein degradation inducing tag and usage thereof
GB201617564D0 (en) * 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
CA3043812A1 (en) 2016-11-15 2018-05-24 Tokyo University Of Science Foundation P53 degradation inducing molecule and pharmaceutical composition
CA3043805A1 (en) 2016-11-15 2018-05-24 Tokyo University Of Science Foundation Ras protein degradation inducing molecule and pharmaceutical composition
EP3635000A4 (de) 2017-05-16 2021-04-14 The Johns Hopkins University Manabodies und anwendungsverfahren
US20230108717A1 (en) * 2021-10-05 2023-04-06 The Penn State Research Foundation Novel methods of creating a protein map and using said map to identify therapeutic targets
US20240010714A1 (en) * 2022-07-10 2024-01-11 Mbrace Therapeutics, Inc. Cell-free methods of recombinant antibody production
CN115876993A (zh) * 2022-11-17 2023-03-31 沈阳农业大学 基于生物膜干涉技术检测病原生物凝集素与唾液酸乳糖亲和力方法的建立

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755144B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Fragments d'anticorps a chaine unique anti-p53 et utilisation
US6630584B1 (en) * 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
US8039594B2 (en) 2005-03-25 2011-10-18 Ramot At Tel-Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses

Also Published As

Publication number Publication date
US20100074908A1 (en) 2010-03-25
EP1863846B1 (de) 2009-07-22
EP1863846A2 (de) 2007-12-12
ATE437185T1 (de) 2009-08-15
US8039594B2 (en) 2011-10-18
US8207309B2 (en) 2012-06-26
JP2008533986A (ja) 2008-08-28
WO2006100681A3 (en) 2007-05-24
WO2006100681A2 (en) 2006-09-28
US20110262447A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
CY1122210T1 (el) Ανθρωπινα αντισωματα anti-sod1
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA202192738A1 (ru) Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
BR112018075626A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco anticorpo
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
DK2142570T3 (da) Anti-EpCam-antistof og anvendelser deraf
EA200700847A1 (ru) Материалы, связывающие прионные белки, и способы их применения
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
EA200701918A1 (ru) Белок липокалин
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
DE602006013029D1 (de) Anti-egfr-antikörper
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
ATE497508T1 (de) Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
BRPI0607323A2 (pt) composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo
EA200702193A1 (ru) Гликозилирование белков

Legal Events

Date Code Title Description
8364 No opposition during term of opposition